Literature DB >> 15606779

Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

Elizabeth A McCaw1, Haibei Hu, Geraldine T Gomez, Andrea L O Hebb, Melanie E M Kelly, Eileen M Denovan-Wright.   

Abstract

Loss of cannabinoid receptors (CB1) occurs prior to neurodegeneration in Huntington's disease (HD). The levels and distribution of CB1 RNA were equivalent in 3-week-old mice regardless of genotype demonstrating that the specific factors and appropriate chromatin structure that lead to the transcription of CB1 were present in the striatum of young R6/2 and R6/1 transgenic HD mice. The expression of the mutant HD transgene led progressively to decreased steady-state levels of CB1 mRNA in neurons of the lateral striatum, which was dependent on the size of the CAG repeat and relative expression of the gene encoding mutant huntingtin (HD). Although it is known that the coding region of CB1 is contained within a single exon in mice, rats and humans, the 5'-untranslated region of the mouse gene remained to be defined. CB1 mRNA is encoded by two exons separated by an 18.4-kb intron. Transcription of CB1 occurred at multiple sites within a GC-rich promoter region upstream of exon 1 encoding the 5'-UTR of CB1. There was no difference in the selection of specific transcription initiation sites associated with higher levels of CB1 expression in the striatum compared to the cortex or between the striata of wild-type and HD transgenic mice. The progressive decline in CB1 mRNA levels in R6 compared to wild-type mice was due to decreased transcription, which is consistent with the hypothesis that mutant huntingtin exerts its effects by altering transcription factor activity. The cell-specific conditions that allow for increased transcription of CB1 in the lateral striatum compared to other forebrain regions from all transcription start sites were affected by the expression of mutant huntingtin in a time-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606779     DOI: 10.1111/j.1432-1033.2004.04460.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  40 in total

1.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 3.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Authors:  Robert B Laprairie; Geraldine T Petr; Yan Sun; Kathryn D Fischer; Eileen M Denovan-Wright; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2018-04-27       Impact factor: 3.921

Review 5.  The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.

Authors:  Lydia K Miller; Lakshmi A Devi
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

6.  Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.

Authors:  Joel D Federspiel; Todd M Greco; Krystal K Lum; Ileana M Cristea
Journal:  Mol Cell Proteomics       Date:  2019-04-30       Impact factor: 5.911

7.  Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

Authors:  Eric A Horne; Jonathan Coy; Katie Swinney; Susan Fung; Allison E T Cherry; William R Marrs; Alipi V Naydenov; Yi Hsing Lin; Xiaocui Sun; C Dirk Keene; Eric Grouzmann; Paul Muchowski; Gillian P Bates; Ken Mackie; Nephi Stella
Journal:  Eur J Neurosci       Date:  2012-11-21       Impact factor: 3.386

8.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

9.  Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

Authors:  Xavier Nadal; Carmen Del Río; Salvatore Casano; Belén Palomares; Carlos Ferreiro-Vera; Carmen Navarrete; Carolina Sánchez-Carnerero; Irene Cantarero; Maria Luz Bellido; Stefan Meyer; Gaetano Morello; Giovanni Appendino; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2017-11-02       Impact factor: 8.739

10.  The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.

Authors:  Eiron Cudaback; William Marrs; Thomas Moeller; Nephi Stella
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.